Page 3 - Nyse Dgx News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Nyse dgx. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Nyse Dgx Today - Breaking & Trending Today
Cwm LLC increased its stake in shares of Quest Diagnostics Incorporated (NYSE:DGX – Free Report) by 1.3% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 18,200 shares of the medical research company’s stock after purchasing an additional 232 shares during the period. […] ....
Quest Diagnostics (NYSE:DGX – Free Report) had its price objective increased by Barclays from $138.00 to $144.00 in a report released on Thursday morning, Benzinga reports. They currently have an equal weight rating on the medical research company’s stock. Several other brokerages have also issued reports on DGX. StockNews.com raised shares of Quest Diagnostics from […] ....
Quest Diagnostics (NYSE:DGX – Get Free Report) issued its quarterly earnings data on Tuesday. The medical research company reported $2.04 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.86 by $0.18, Briefing.com reports. The business had revenue of $2.37 billion for the quarter, compared to analysts’ expectations of $2.29 billion. Quest […] ....
Quest Diagnostics (NYSE:DGX – Get Free Report) released its earnings results on Tuesday. The medical research company reported $2.04 earnings per share for the quarter, beating analysts’ consensus estimates of $1.86 by $0.18, Briefing.com reports. The firm had revenue of $2.37 billion during the quarter, compared to the consensus estimate of $2.29 billion. Quest Diagnostics […] ....
Quest Diagnostics (NYSE:DGX – Get Free Report) had its target price boosted by investment analysts at Citigroup from $135.00 to $145.00 in a report issued on Wednesday, Benzinga reports. The brokerage presently has a “neutral” rating on the medical research company’s stock. Citigroup’s target price suggests a potential upside of 5.27% from the company’s previous […] ....